ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.73
0.23%
US Tech 100
21,176.00
-0.11%
S&P 500
6,037.59
1.06%
US Dollar vs CAD
1.44108
0.39%
Bitcoin
95,729.00
0.05%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Rhythm Pharmaceuticals Inc (RYTM)

  7. Rhythm Pharmaceuticals Inc (RYTM) News

Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc (RYTM)

NASDAQ
56.54
0.69
(1.24%)
At close: December 26 3:00PM
Delayed by 15 minutes
56.54
0.01
( 0.02% )
After Hours: 5:38PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

RYTM News

Official News Only

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
November 13 2024
RYTM (1.24%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
November 13 2024
RYTM (1.24%)

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Edgar (US Regulatory)
November 13 2024
RYTM (1.24%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
November 12 2024
RYTM (1.24%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
November 08 2024
RYTM (1.24%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
November 07 2024
RYTM (1.24%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
November 06 2024
RYTM (1.24%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
November 06 2024
RYTM (1.24%)

Form 8-K - Current report
Edgar (US Regulatory)
November 05 2024
RYTM (1.24%)

RYTM Discussion

View Posts
Monksdream Monksdream 2 months ago
RYTM 10Q 11/5
👍️0
Monksdream Monksdream 3 months ago
RYTM approaching a 52=week high
👍️0
Monksdream Monksdream 10 months ago
RYTM new 52 week high
👍️0
Monksdream Monksdream 11 months ago
RYTM new 52 week high

👍️0
Monksdream Monksdream 1 year ago
RYTM new 52 week high
👍️0
Monksdream Monksdream 1 year ago
RYTM new 52 week high
👍️0
midastouch017 midastouch017 2 years ago
In my view ORMP is better than RYTM from investment perspective.

Sigh, how wrong can one be!
(including me - of course)
👍️0
bandit007 bandit007 2 years ago
Why am I the only one posting here? This thing has been steady up over100% since I started posting here. Even on a day like today when most others are red. Another green day here!! $RYTM
👍️0
bandit007 bandit007 2 years ago
When $20 breaks and holds this will fly! IMO
👍️0
bandit007 bandit007 2 years ago
Looking like it’s ready to move up again here. Possible bounce off of support.
👍️0
Amatuer17 Amatuer17 2 years ago
Some you win some you lose - I had a lot of conviction but later lost faith after that time and sold completely.
👍️0
Laszlo1 Laszlo1 2 years ago
Sorry
👍️0
bandit007 bandit007 2 years ago
Thanks for posting. Breakout mode! GL
👍️0
conix conix 2 years ago
RYTM Chart

👍️0
bandit007 bandit007 2 years ago
I’m liking the chart on this one.
👍️0
willlbone willlbone 3 years ago
Two year slide continues.
👍️0
Amatuer17 Amatuer17 3 years ago
I lost money on RYTM and booked losses already.
👍️0
midastouch017 midastouch017 3 years ago
In my view ORMP is better than
RYTM from investment perspective.

Spot on!
👍️0
Amatuer17 Amatuer17 4 years ago
In my view ORMP is better than RYTM from investment perspective.

The current market capon $255 million allows it to be a 10 bagger ($2.55 B) - speciall that it has first in class product and huge unmet market.

RTYM also has first in class product with unmet needs but it is rare disease and not many outside US can afford
👍️0
Amatuer17 Amatuer17 4 years ago
Agree - it is good company
Will take time to make money but proof of product is there.

The valuation is fair at this point - upside maybe 50-70% by end of the year based on how they price and are able show sale.

The payment cycle with insurance will be key as the product is very high priced -
👍️0
fishhunter fishhunter 4 years ago
I started building a major position. And already a little green!
Quite the biotech soon last couple weeks= opportunity!
👍️0
Amatuer17 Amatuer17 4 years ago
For some reason it is tanking now -sale the news
👍️0
midastouch017 midastouch017 4 years ago
RYTM is not cheap as it has market cap of $832 million for pre-revenue biotech - so it is richly valued.


Are you kidding? You know what the mc is today?

Market Cap 1.737B

Since you introduced me to this company it has doubled
in price, if it was richly valued then, what is it now?

But this is besides my previous point - namely i 'missed'
the entry point.
👍️0
Amatuer17 Amatuer17 4 years ago
You can actually wait for some time and buy - this is a long term play
👍️0
midastouch017 midastouch017 4 years ago
I missed out this one!

👍️0
Amatuer17 Amatuer17 4 years ago
Just amazing results - they are starting new basket trials.

The product is approved for one indication so it is now label expansion - the pricing power is amazing. This should really take off. Is it next Alexion in terms of rare disease treatment and pricing power?
👍️0
Amatuer17 Amatuer17 4 years ago
Head the conf call - It was good call.

The results are much better that what PR said. Slide 14-15 shows correct numbers which were clarified by them.

Real numbers
Total patients - 31
Total BBS patients - 28
No of patients dropped - 4
Total no of patients relevant - 24

No of patients with 5%+ weight reduction - 16 = 67% that is double the number compared to combined number of 34.5%

No of patients who lost more than 10% weight - 11 out of 24 (45.8%)
Mean reduction - 14.5%

Compared to 1st approval which had few hundred population, BBS has 1000-1500 target population in US alone

This is large population for rare disease - @ $200k per year - this is a big market.

Also this is not a gene therapy - so drug is needed forever and it keeps the weight down.

Last point - All genes targeted in basket trial are in BBS category (strong or very strong relationship) so they think the basket trial results may be positive.

Cash enough till 2022. I think if stock goes down further, it will be good opportunity to buy - stock could give 50% returns from here in 6 months based on basket trial results.
👍️0
Amatuer17 Amatuer17 4 years ago
Phase 3 results - BBS stat significant -AL not

Market reaction is not good. Conf call will give more info

https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-positive-topline-120000038.html
👍️0
Amatuer17 Amatuer17 4 years ago
Finally - Approval

“Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™(setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency”

Another good news - voucher that they can sell or use for next approval

“With this approval, the FDA issued a Rare Pediatric Disease Priority Review Voucher (PRV) to Rhythm. The PRV can be redeemed to receive priority review for any subsequent marketing application or sold or transferred to other companies for their programs.”


https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-fda-approval-123000486.html
👍️0
grich1 grich1 4 years ago
That’s a big run with PDUFA being in November. I took some profit but still in the game and will buy 100% back if reversal. Outstanding shares only @ 44M and float 30M. PT @ $33.
👍️0
midastouch017 midastouch017 4 years ago
Good call!

👍️0
Amatuer17 Amatuer17 4 years ago
What is happening? Looks good
👍️0
midastouch017 midastouch017 4 years ago
Not so sure the last few years.

I am no US citizen, i would not like to comment
about US politics. We have enough political
unrest in my part of the globe, in Israel.

I’ve done enough DD on PSTI and RDHL

I was a heavy investor in PSTI, sold it all a few
weeks ago at a big loss, and not looking back.

RDHL, otoh is a serious company, i am sure it will
go places, high places that is.

As for RYTM, I have no funds at the moment, but
will start a position soon.

GLTY
👍️0
Amatuer17 Amatuer17 4 years ago
RYTM is not cheap as it has market cap of $832 million for pre-revenue biotech - so it is richly valued.

It has 70 employees - more than many biotech at this stage but not sufficient for marketing the drug. So they have to find a partner or go with buyout.

The good news is - the co has $228 milllion plus cash and it will allow them to run till end of 2021.

They are in niche area and there is no other competition nearby. If the drug can address genetic obesity - they have 80,000 target audience in US alone.

If the drug can be tested on genetic obesity/weight loss, it will be gold mine.
👍️0
pennyrich pennyrich 4 years ago
Not so sure the last few years. But what the heck.
I’m new on RYTM. I’ve done enough DD on PSTI and RDHL to hold a small 500 share stake in both. I’ll do some extra digging here because the stakes are much higher. The last 3 months haven’t been bad on the other two.
GLTUA
Pr
👍️0
midastouch017 midastouch017 4 years ago
Sure. A free country, isn't it?

👍️0
pennyrich pennyrich 4 years ago
Can anyone play???
👍️0
midastouch017 midastouch017 4 years ago
Thanks for the heads up Amatuer17,
i'll dig into it over the weekend.

👍️0
Amatuer17 Amatuer17 4 years ago
Welcome to the board. Hope we all make money

This is a PDUFA based play

PDUFA date - 27th Nov

Disease - rare disease - obesity based on genetics

MOA - impacts the MC4PA gene that controls obesity and hunger. They have 4 more trials for other sub areas also in advance stage.

As per conf call - they are looking at pricing from $200k to $400k per year Patient population for this approval - around 1000

https://ir.rhythmtx.com/static-files/fd4e0919-4d82-47e0-afe3-8cd9b5151490
👍️0

Your Recent History

NASDAQ
RYTM
Rhythm Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads